Drug Trial Radar · NCT07328529
Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Azevan PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- Congressionally Directed Medical Research Programs
- First posted
- Jan 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if drug SRX246 works to treat irritability, agitation, aggression and self-injury (IAAS) behaviors in adult males with Fragile X Syndrome (FXS). It will also learn about the safety of drug SRX246. The main questions it aims to answer are: * Does drug SRX246 lower the number of times participants experience IAAS behaviors? * What medical problems do participants have when taking drug SRX246? Researchers will compare drug SRX246 to a placebo (a look-alike substance that contains no drug) to see if drug SRX246 works to treat IAAS behaviors. Participants will: * Take drug SRX246 or a placebo every day for up to 8 months * Have weekly checkups by phone or video to answer study questions * Have periodically scheduled home visits by nurses to conduct medical check-ups and tests * Keep a diary of their symptoms
Conditions
- Aggressive Behavior in Fragile X Syndome
Interventions
SRX246Drug
SRX246 120mg capsules for oral administration
PlaceboDrug
Placebo capsules for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Aberrant Behavior ChecklistTime frame: Over an 8 month period
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of California, Davis, MIND Institute
Sacramento, California
Rush University Medical Center
Chicago, Illinois
Cincinnati Children's Hospital
Cincinnati, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.